NCT00520806View on ClinicalTrials.gov

Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

1,161

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Heart Failure, Congestive
Interventions
DRUG

Relaxin

Intravenous infusion for 48 h at 30 ug/kg/day

DRUG

Placebo

Intravenous infusion for 48 h

Trial Locations (3)

48201

Wayne State University/Detroit Receiving Hospital, Detroit

60611

Northwestern University, Chicago

Unknown

Heart Institute, Safed

All Listed Sponsors
lead

Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies

INDUSTRY

NCT00520806 - Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure | Biotech Hunter | Biotech Hunter